Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022

Author's Avatar
Nov 04, 2022

New Data Detail Efficacy of HDAC6 Inhibition Compared to Empagliflozin in Model of Heart Failure with Preserved Ejection Fraction